Skip to main content

Table 1 Categorisation 1: non-high FeNO and non-high blood eosinophils vs. high FeNO and high blood eosinophils

From: Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations

Characteristics

Non-high FeNO and non-high blood eosinophils (n = 27)

High FeNO and high blood eosinophils (n = 27)

p-value

Sex

 n (% non-missing)

27 (100.0)

27 (100.0)

1.0000

 Male

10 (37.0)

10 (37.0)

 

Age

 n (% non-missing)

27 (100.0)

27 (100.0)

0.9379

 Mean (SD)

43.5 (18.8)

43.3 (19.0)

 

 Median (IQR)

41.0 (37.0)

41.0 (37.0)

 

Age group

 n (% non-missing)

27 (100.0)

27 (100.0)

1.0000

 Under 35

12 (44.4)

12 (44.4)

 

 35–65

9 (33.3)

9 (33.3)

 

 66–80

6 (22.2)

6 (22.2)

 

Smoking status

 n (% non-missing)

27 (100.0)

27 (100.0)

0.7645

 Non-smoker

13 (48.1)

14 (51.9)

 

 Ex-smoker

1 (3.7)

2 (7.4)

 

 Current smoker

13 (48.1)

11 (40.7)

 

BMI

   

 n (% non-missing)

23 (85.2)

26 (96.3)

0.4346

 Mean (SD)

27.7 (7.2)

26.9 (6.4)

 

 Median (IQR)

26.8 (5.5)

25.5 (8.4)

 

Active eczema diagnosisa

 n (% non-missing)

27 (100.0)

27 (100.0)

0.6387

 Yes

3 (11.1)

2 (7.4)

 

Active rhinitis diagnosisa

 n (% non-missing)

27 (100.0)

27 (100.0)

0.2482

 Yes

7 (25.9)

11 (40.7)

 

Eczema diagnosis

 n (% non-missing)

27 (100.0)

27 (100.0)

0.7801

 Yes

10 (37.0)

11 (40.7)

 

Rhinitis diagnosis

 n (% non-missing)

27 (100.0)

27 (100.0)

0.1628

 Yes

8 (29.6)

13 (48.1)

 

IHD diagnosis

 n (% non-missing)

27 (100.0)

27 (100.0)

0.5525

 Yes

2 (7.4)

1 (3.7)

 

Heart failure diagnosis

 n (% non-missing)

27 (100.0)

27 (100.0)

 

 Yes

0 (0.0)

0 (0.0)

 

Hypertension diagnosis

 n (% non-missing)

27 (100.0)

27 (100.0)

0.4436

 Yes

5 (18.5)

3 (11.1)

 

Diabetes diagnosis

 n (% non-missing)

27 (100.0)

27 (100.0)

 

 Yes

0 (0.0)

0 (0.0)

 

GERD active diagnosis

 n (% non-missing)

27 (100.0)

27 (100.0)

0.3128

 Yes

1 (3.7)

0 (0.0)

 

Predicted peak flow

 n (% non-missing)

14 (51.9)

20 (74.1)

0.9721

 Mean (SD)

488.9 (53.4)

505.8 (74.9)

 

 Median (IQR)

482.7 (47.2)

478.3 (127.7)

 

ICS/LABA prescriptions per patient

 n (% non-missing)

27 (100.0)

27 (100.0)

0.6546

 Mean (SD)

3.6 (4.3)

3.2 (2.5)

 

 Median (IQR)

1.0 (7.0)

3.0 (5.0)

 

Mono ICS prescriptions per patient

 n (% non-missing)

27 (100.0)

27 (100.0)

0.4898

 Mean (SD)

1.2 (1.9)

1.0 (2.2)

 

 Median (IQR)

0.0 (2.0)

0.0 (1.0)

 

Mean daily SABA dosage (µg)

 n (% non-missing)

27 (100.0)

27 (100.0)

0.5066

 < 100

8 (29.6)

6 (22.2)

 

 100–200

11 (40.7)

8 (29.6)

 

 201–400

6 (22.2)

8 (29.6)

 

 > 400

2 (7.4)

5 (18.5)

 

ICS adherenceb

 n (% non-missing)

27 (100.0)

27 (100.0)

0.7158

 Mean (SD)

57.1 (39.3)

52.3 (32.9)

 

 Median (IQR)

54.8 (54.8)

49.3 (35.7)

 
  1. All values in the table are n (%) unless otherwise specified. High FeNO defined as ≥ 50 ppb; non-high FeNO < 25 ppb; high blood eosinophil count defined as ≥ 0.300 × 109 cells/L; non-high blood eosinophil count < 0.300 × 109 cells/L
  2. ATS American Thoracic Society, BMI body mass index, FeNO fractional exhaled nitric oxide, GERD gastroesophageal reflux disease, ICS inhaled corticosteroid, IHD ischaemic heart disease, IQR interquartile range, LABA long-acting β2-agonist, ppb parts per billion, SABA short-acting β2-agonist, SD standard deviation
  3. aActive denotes diagnosed in the year before FeNO reading or treated in the year before FeNO reading
  4. bMedication Possession Ratio was calculated by dividing the total of 1 day’s supply by the total number of days evaluated, multiplied by 100%. The evaluation period for all patients was 365 days in the study year
Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us